Herpetic tracheitis in association with rituximab therapy by Thong, Lorraine et al.
Title Herpetic tracheitis in association with rituximab therapy
Author(s) Thong, Lorraine; Plant, Barry J.; McCarthy, Julie; Murphy, Desmond M.
Publication date 2016-05-05
Original citation Thong, L., Plant, B. J., McCarthy, J. and Murphy, D. M. (2016)
'Herpetic tracheitis in association with rituximab therapy', Respirology
Case Reports, 4(4), e00158. doi:10.1002/rcr2.158
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://dx.doi.org/10.1002/rcr2.158
Access to the full text of the published version may require a
subscription.
Rights © 2016 The Authors. Respirology Case Reports published by John
Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society
of Respirology. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any medium, provided the
original work is properly cited, the use is non-commercial and no
modifications or adaptations are made.
https://creativecommons.org/licenses/by-nc/4.0/
Item downloaded
from
http://hdl.handle.net/10468/3497
Downloaded on 2017-02-12T14:44:44Z
Herpetic tracheitis in association with rituximab therapy
Lorraine Thong1, Barry J Plant1, Julie McCarthy2 & Desmond M Murphy1
1Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.
2Department of Cytopathology, Cork University Hospital, Cork, Ireland.
Keywords
Herpes simplex, immunosuppression, non-
Hodgkin’s lymphoma, rituximab, tracheitis.
Correspondence
Desmond M Murphy, Department of
Respiratory Medicine, Cork University Hospital,
Wilton, Cork, County Cork, Ireland. E-mail:
Desmond.murphy@hse.ie
Received: 25 November 2015; Revised:
24 February 2016; Accepted: 06 March 2016
Respirology Case Reports, 4 (4), 2016, e00158
doi: 10.1002/rcr2.158
Abstract
A 58-year old lady under active follow-up with the respiratory services at our
institution for bronchiectasis secondary to hypogammaglobulinaemia presented
with hoarseness and haemoptysis. She was also receiving rituximab maintenance
therapy for follicular lymphoma. Bronchoscopy demonstrated vesicular lesions on
her vocal cords and trachea, conﬁrmed as herpes simplex virus (HSV) on cytological
analysis of brushings. She responded well to intravenous valacyclovir. Rituximab is
increasingly utilised in the treatment of haematological and auto-immune disorders.
This case highlights the potential of this drug to potentiate susceptibility to infection
in an already immunocompromised individual.
Introduction
Rituximab is a chimeric anti-CD20 antibody increasingly utilised
for treating autoimmune diseases and haematological disorders.
It works via three independent mechanisms of action: antibody-
dependent cellular cytotoxicity, complement-mediated cytoto-
xicity, and apoptosis. The therapeutic value of rituximab in
non-Hodgkin’s lymphoma is a result of the expression of
CD20 on the cell surface of the majority of B cells [1].
A recently published report examining the long-term safety
proﬁle of rituximab therapy in lymphoma concluded that
infection-related events were higher in patients treated with
rituximab, although overall survival was improved [2].
Herpes simplex virus (HSV)-related infection associated with
rituximab therapy has been reported. A male patient with
lymphoma treated with rituximab presented with oral pain
and odynophagia. He was diagnosed with HSV mucositis [3].
Lower respiratory tract infection by HSV primarily occurs
in patients who are profoundly immunocompromised or
have sustained trauma to their tracheal epithelium. In an
immunocompromised host, the condition can be progressive
and fatal. Its pathogenesis remains unclear, with some authors
suggesting possible extension or aspiration of oropharyngeal
HSV, whilst there is some evidence to support a role for
haematogenous spread [4].
Case report
A 58-year old lady was under respiratory follow-up at our
institution for bronchiectasis, which had developed secondary
to hypogammaglobulinaemia. At one of her routine out-
patient visits, she complained of a one-week history of
hoarseness and general malaise. She had a single episode of
haemoptysis. Furthermore, she reported an increased
exacerbation frequency in the preceding months. She had
received rituximab therapy 1week prior to her clinic review.
She had started on maintenance rituximab therapy appro-
ximately 6months prior to that, and received at total of
3 cycles of same.
Other than her bronchiectasis and follicular lymphoma,
her past medical history was notable for cryoglobulinaemia,
previous breast cancer, and chronic kidney disease.
Her other regular medications included azithromycin,
tiotropium inhaler, montelukast, salmeterol/ﬂuticasone inha-
ler, pravastatin, and nitrofurantoin.
At clinical presentation, the physical examination
demonstrated oxygen saturations of 93% on room air, a pulse
rate of 90 beats per minute, and a blood pressure of
120/80mmHg. Apart from mild expiratory wheeze and
scattered inspiratory crackles on the auscultation of her lung
ﬁelds, the physical examination was unremarkable.
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Initial haematological investigations revealed lymphopenia
(0.38×109/L), raised C-reactive protein (126mg/L), and
lactate dehydrogenase (989U/L). The computed tomography
of the thorax performed was notable for two left upper lobe
nodules, one measuring 15mm with central cavitation, and
the second measuring 8mm with a surrounding ground
glass halo.
Intravenous piperacillin/tazobactam was empirically
commenced prior to a bronchoscopy. The bronchoscopy
revealed the presence of vesicular tracheal lesions (see Fig.
1). Endobronchial brushings conﬁrmed a diagnosis of
herpetic tracheitis (see Fig. 2). She was commenced on
intravenous valacyclovir. Piperacillin/tazobactam was
continued, and an antifungal agent, intravenous caspofungin,
was added to her therapeutic regimen-pending cultures.
Bronchoalveolar lavage subsequently grew Pseudomonas
aeruginosa. She completed a 2-week course of intravenous
antimicrobial therapy. A repeat bronchoscopy-performed
post-treatment revealed a complete resolution of her tracheal
lesions. She was discharged well on long term prophylactic
antiviral therapy thereafter, and remained on rituximab
therapy.
Discussion
The diagnosis of lower respiratory tract HSV infection should
be based initially on cytological and/or histological ﬁndings.
Bronchoscopy is valuable for visualizing typical ulcerations
or membranes in the respiratory tract, and for improving
the sensitivity and speciﬁcity of the cytological diagnosis.
Reactivation of viral infection is common in patients with
solid tumour or haematological malignancy. Incidence and
severity are dependent on the extent of cellular immu-
nosuppression. It is therefore possible that rituximab adds
additional risk. Antiviral agents have demonstrated clinical
efﬁcacy in treating both mucocutaneous and pulmonary
HSV infections. Antiviral prophylaxis may be effective in
preventing viral reactivation [5].
In conclusion, we present a case of HSV lower respiratory
tract infection in a patient undergoing treatment with
rituximab, highlighting the potential of this agent to induce
immunosuppression.
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Figure 2. Photomicrograph of bronchial brushing cytospin preparation
stained with Papanicolaou stain (×60). A mature squamous cell (top
right) and normal endobronchial epithelial cell (top left) are seen. Three
virally infected cells show ground glass inclusions (nuclear enlargement,
smudging of nuclear chromatin, and beading of nuclear membrane).
These are typical cytomorphologies of Herpes Simplex Virus (HSV).
Figure 1. (A) Vesicular rashes seen on the tracheal wall, consistent with herpetic tracheitis. (B) Resolutions of lesions 2weeks post-treatment with antiviral
therapy.
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